{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:14:57Z","timestamp":1790828097992,"version":"4.1.0"},"reference-count":59,"publisher":"Innovative Healthcare Institute","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>In recent years, cancer treatment has evolved, and new therapies have been introduced with significant improvement in prognosis. The immunotherapies stand out owing to their efficacy and remission rate. Chimeric antigen receptor (CAR) T-cell therapy is a part of this new era of therapies. Chimeric antigen receptor T-cell therapy is a form of adoptive cellular therapy that uses a genetically encoded CAR in modified human T cells to target specific tumor antigens in a nonconventional, non-major histocompatibility complex (MHC) protein presentation. Chimeric antigen receptor T-cell therapy successfully identifies tumor antigens and through activation of T cells destroys tumoral cells. It has been found to efficiently induce remission in patients who have been previously treated for B-cell malignancies and have persistent disease. As the use of this novel therapy increases, its potential side effects also have become more evident, including major complications like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Cytokine release syndrome is a major systemic inflammatory process as a result of massive cytokine production by the proliferating and activated CAR T cells in which multiple interleukins and immune cells contribute to the inflammatory response. Cytokine release syndrome has been associated with cardiovascular life-threatening complications including hypotension, shock, tachycardia, arrhythmias, left ventricular dysfunction, heart failure, and cardiovascular death. Arrhythmias, among its major complications, vary from asymptomatic prolonged corrected QT interval (QTc) to supraventricular tachycardia, atrial fibrillation, flutter, and ventricular arrhythmias like Torsade de pointes. This article focuses on the cardiovascular complications and arrhythmias associated with CRS and CAR T-cell therapy.<\/jats:p>","DOI":"10.36401\/jipo-20-10","type":"journal-article","created":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T16:55:25Z","timestamp":1596732925000},"page":"113-120","source":"Crossref","is-referenced-by-count":26,"title":["Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy: The Cytokine Release Syndrome and Associated Arrhythmias"],"prefix":"10.36401","volume":"3","author":[{"given":"Cesar Clavijo","family":"Simbaqueba","sequence":"first","affiliation":[{"name":"Department of General Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Patarroyo","family":"Aponte","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Texas Health System, Memorial Hermann Hospital, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Deswal","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas L.","family":"Palaskas","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cezar","family":"Iliescu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiman","family":"Jahangir","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Vanderbilt University Medical Center, Vanderbilt, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric H.","family":"Yang","sequence":"additional","affiliation":[{"name":"UCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine, University of California at Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael E.","family":"Steiner","sequence":"additional","affiliation":[{"name":"Department of Lymphoma-Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Lopez-Mattei","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22027","published-online":{"date-parts":[[2020,7,20]]},"reference":[{"key":"2021072121212171600_i2590-017X-3-3-113-b01","unstructured":"American Cancer Society. Cancer facts & figures 2019.https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2019\/cancer-facts-and-figures-2019.pdf. Accessed June 6, 2020."},{"key":"2021072121212171600_i2590-017X-3-3-113-b02","doi-asserted-by":"crossref","unstructured":"Kroschinsky F, Stolzel F, von Bonin S, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. 2017; 21: 89.","DOI":"10.1186\/s13054-017-1678-1"},{"key":"2021072121212171600_i2590-017X-3-3-113-b03","unstructured":"U.S. Food and Drug Administration. FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma. 2017. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-car-t-cell-therapy-treat-adults-certain-types-large-b-cell-lymphoma. Accessed June 6, 2020."},{"key":"2021072121212171600_i2590-017X-3-3-113-b04","doi-asserted-by":"crossref","unstructured":"Ye B, Stary CM, Li X, Gao Q, Kang C, Xiong X. Engineering chimeric antigen receptor-T cells for cancer treatment. Mol Cancer. 2018; 17: 32.","DOI":"10.1186\/s12943-018-0814-0"},{"key":"2021072121212171600_i2590-017X-3-3-113-b05","doi-asserted-by":"crossref","unstructured":"Ganatra S, Parikh R, Neilan TG. Cardiotoxicity of immune therapy. Cardiol Clin. 2019; 37: 385\u2013 397.","DOI":"10.1016\/j.ccl.2019.07.008"},{"key":"2021072121212171600_i2590-017X-3-3-113-b06","doi-asserted-by":"crossref","unstructured":"Strati P, Neelapu SS. Chimeric antigen receptor-engineered T cell therapy in lymphoma. Curr Oncol Rep. 2019; 21: 38.","DOI":"10.1007\/s11912-019-0789-z"},{"key":"2021072121212171600_i2590-017X-3-3-113-b07","doi-asserted-by":"crossref","unstructured":"Neelapu SS. Managing the toxicities of CAR T-cell therapy. Hematol Oncol. 2019; 37(suppl 1): 48\u2013 52.","DOI":"10.1002\/hon.2595"},{"key":"2021072121212171600_i2590-017X-3-3-113-b08","doi-asserted-by":"crossref","unstructured":"Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010; 116: 4099\u2013 4102.","DOI":"10.1182\/blood-2010-04-281931"},{"key":"2021072121212171600_i2590-017X-3-3-113-b09","doi-asserted-by":"crossref","unstructured":"Kochenderfer JN, Somerville RPT, Lu T, et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol. 2017; 35: 1803\u2013 1813.","DOI":"10.1200\/JCO.2016.71.3024"},{"key":"2021072121212171600_i2590-017X-3-3-113-b10","doi-asserted-by":"crossref","unstructured":"Brudno JN, Somerville RP, Shi V, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016; 34: 1112\u2013 1121.","DOI":"10.1200\/JCO.2015.64.5929"},{"key":"2021072121212171600_i2590-017X-3-3-113-b11","doi-asserted-by":"crossref","unstructured":"Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019; 380: 1726\u2013 1737.","DOI":"10.1056\/NEJMoa1817226"},{"key":"2021072121212171600_i2590-017X-3-3-113-b12","doi-asserted-by":"crossref","unstructured":"Wang ML, Munoz J, Goy A, et al. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients (Pts) with relapsed\/refractory (R\/R) mantle cell lymphoma (MCL): results of the phase 2 ZUMA-2 study. Blood. 2019; 134(suppl 1): 754.","DOI":"10.1182\/blood-2019-126064"},{"key":"2021072121212171600_i2590-017X-3-3-113-b13","doi-asserted-by":"crossref","unstructured":"Yan W, Hu H, Tang B. Advances of chimeric antigen receptor T cell therapy in ovarian cancer. Onco Targets Ther. 2019; 12: 8015\u2013 8022.","DOI":"10.2147\/OTT.S203550"},{"key":"2021072121212171600_i2590-017X-3-3-113-b14","doi-asserted-by":"crossref","unstructured":"Zhang RY, Wei D, Liu ZK, et al. Doxycycline inducible chimeric antigen receptor T cells targeting CD147 for hepatocellular carcinoma therapy. Front Cell Dev Biol. 2019; 7: 233.","DOI":"10.3389\/fcell.2019.00233"},{"key":"2021072121212171600_i2590-017X-3-3-113-b15","doi-asserted-by":"crossref","unstructured":"Cohen AD, Raje N, Fowler JA, Mezzi K, Scott EC, Dhodapkar MV. How to train your T cells: overcoming immune dysfunction in multiple myeloma. Clin Cancer Res.2019 Oct 31 [epub ahead of print] DOI: 10.1158\/1078-0432.CCR-19-2111.","DOI":"10.1158\/1078-0432.CCR-19-2111"},{"key":"2021072121212171600_i2590-017X-3-3-113-b16","doi-asserted-by":"crossref","unstructured":"Jiang C, Zhao W, Qin M, Jin M, Chang L, Ma X. CD56-chimeric antigen receptor T-cell therapy for refractory\/recurrent rhabdomyosarcoma: a 3.5-year follow-up case report. Medicine. 2019; 98: e17572.","DOI":"10.1097\/MD.0000000000017572"},{"key":"2021072121212171600_i2590-017X-3-3-113-b17","doi-asserted-by":"crossref","unstructured":"Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017; 130: 2295\u2013 2306.","DOI":"10.1182\/blood-2017-06-793141"},{"key":"2021072121212171600_i2590-017X-3-3-113-b18","doi-asserted-by":"crossref","unstructured":"Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371: 1507\u2013 1517.","DOI":"10.1056\/NEJMoa1407222"},{"key":"2021072121212171600_i2590-017X-3-3-113-b19","doi-asserted-by":"crossref","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015; 385: 517\u2013 528.","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"2021072121212171600_i2590-017X-3-3-113-b20","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018; 15: 47\u2013 62.","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"2021072121212171600_i2590-017X-3-3-113-b21","doi-asserted-by":"crossref","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016; 127: 3321\u2013 3330.","DOI":"10.1182\/blood-2016-04-703751"},{"key":"2021072121212171600_i2590-017X-3-3-113-b22","doi-asserted-by":"crossref","unstructured":"Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019; 25: 625\u2013 638.","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"2021072121212171600_i2590-017X-3-3-113-b23","doi-asserted-by":"crossref","unstructured":"Fry TJ, Shah NN, Orentas RJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018; 24: 20\u2013 28.","DOI":"10.1038\/nm.4441"},{"key":"2021072121212171600_i2590-017X-3-3-113-b24","doi-asserted-by":"crossref","unstructured":"Aldoss I, Khaled SK, Budde E, Stein AS. Cytokine release syndrome with the novel treatments of acute lymphoblastic leukemia: pathophysiology, prevention, and treatment. Curr Oncol Rep. 2019; 21: 4.","DOI":"10.1007\/s11912-019-0753-y"},{"key":"2021072121212171600_i2590-017X-3-3-113-b25","doi-asserted-by":"crossref","unstructured":"Burstein DS, Maude S, Grupp S, Griffis H, Rossano J, Lin K. Cardiac profile of chimeric antigen receptor T cell therapy in children: a single-institution experience. Biol Blood Marrow Transplant. 2018; 24: 1590\u2013 1595.","DOI":"10.1016\/j.bbmt.2018.05.014"},{"key":"2021072121212171600_i2590-017X-3-3-113-b26","doi-asserted-by":"crossref","unstructured":"Ganatra S, Carver JR, Hayek SS, et al. Chimeric antigen receptor T-cell therapy for cancer and heart: JACC Council perspectives. J Am Coll Cardiol. 2019; 74: 3153\u2013 3163.","DOI":"10.1016\/j.jacc.2019.10.049"},{"key":"2021072121212171600_i2590-017X-3-3-113-b27","doi-asserted-by":"crossref","unstructured":"Alvi RM, Frigault MJ, Fradley MG, et al. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol. 2019; 74: 3099\u2013 3108.","DOI":"10.1016\/j.jacc.2019.10.038"},{"key":"2021072121212171600_i2590-017X-3-3-113-b28","doi-asserted-by":"crossref","unstructured":"Sano D, Nastoupil LJ, Fowler NH, et al. Safety of axicabtagene ciloleucel CD19 CAR T-cell therapy in elderly patients with relapsed or refractory large B-cell lymphoma. Blood. 2018; 132(suppl 1): 96.","DOI":"10.1182\/blood-2018-99-120013"},{"key":"2021072121212171600_i2590-017X-3-3-113-b29","doi-asserted-by":"crossref","unstructured":"Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med.2014; 6: 224ra25.","DOI":"10.1126\/scitranslmed.3008226"},{"key":"2021072121212171600_i2590-017X-3-3-113-b30","doi-asserted-by":"crossref","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015; 33: 540\u2013 549.","DOI":"10.1200\/JCO.2014.56.2025"},{"key":"2021072121212171600_i2590-017X-3-3-113-b31","doi-asserted-by":"crossref","unstructured":"Cameron BJ, Gerry AB, Dukes J, et al. Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med.2013; 5: 197ra03.","DOI":"10.1126\/scitranslmed.3006034"},{"key":"2021072121212171600_i2590-017X-3-3-113-b32","doi-asserted-by":"crossref","unstructured":"Linette GP, Stadtmauer EA, Maus MV, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013; 122: 863\u2013 871.","DOI":"10.1182\/blood-2013-03-490565"},{"key":"2021072121212171600_i2590-017X-3-3-113-b33","doi-asserted-by":"crossref","unstructured":"Sato R, Nasu M. A review of sepsis-induced cardiomyopathy. J Intens Care. 2015; 3: 48.","DOI":"10.1186\/s40560-015-0112-5"},{"key":"2021072121212171600_i2590-017X-3-3-113-b34","doi-asserted-by":"crossref","unstructured":"Kochenderfer JN, Dudley ME, Carpenter RO, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013; 122: 4129\u2013 4139.","DOI":"10.1182\/blood-2013-08-519413"},{"key":"2021072121212171600_i2590-017X-3-3-113-b35","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2018; 380: 45\u2013 56.","DOI":"10.1056\/NEJMoa1804980"},{"key":"2021072121212171600_i2590-017X-3-3-113-b36","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377: 2531\u2013 2544.","DOI":"10.1056\/NEJMoa1707447"},{"key":"2021072121212171600_i2590-017X-3-3-113-b37","doi-asserted-by":"crossref","unstructured":"Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018; 378: 439\u2013 448.","DOI":"10.1056\/NEJMoa1709866"},{"key":"2021072121212171600_i2590-017X-3-3-113-b38","doi-asserted-by":"crossref","unstructured":"Kouvas N, Kontogiannis C, Georgiopoulos G, et al. The complex crosstalk between inflammatory cytokines and ventricular arrhythmias. Cytokine. 2018; 111: 171\u2013 177.","DOI":"10.1016\/j.cyto.2018.08.007"},{"key":"2021072121212171600_i2590-017X-3-3-113-b39","doi-asserted-by":"crossref","unstructured":"Vonderlin N, Siebermair J, Kaya E, Kohler M, Rassaf T, Wakili R. Critical inflammatory mechanisms underlying arrhythmias. Herz. 2019; 44: 121\u2013 129.","DOI":"10.1007\/s00059-019-4788-5"},{"key":"2021072121212171600_i2590-017X-3-3-113-b40","doi-asserted-by":"crossref","unstructured":"Bruins P, te Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997; 96: 3542\u2013 3548.","DOI":"10.1161\/01.CIR.96.10.3542"},{"key":"2021072121212171600_i2590-017X-3-3-113-b41","doi-asserted-by":"crossref","unstructured":"Ishii Y, Schuessler RB, Gaynor SL, et al. Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduction and atrial fibrillation. Circulation. 2005; 111: 2881\u2013 2888.","DOI":"10.1161\/CIRCULATIONAHA.104.475194"},{"key":"2021072121212171600_i2590-017X-3-3-113-b42","doi-asserted-by":"crossref","unstructured":"Mathew JP, Fontes ML, Tudor IC, et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA. 2004; 291: 1720\u2013 1729.","DOI":"10.1001\/jama.291.14.1720"},{"key":"2021072121212171600_i2590-017X-3-3-113-b43","doi-asserted-by":"crossref","unstructured":"Lamm G, Auer J, Weber T, Berent R, Ng C, Eber B. Postoperative white blood cell count predicts atrial fibrillation after cardiac surgery. J Cardiothorac Vasc Anesth. 2006; 20: 51\u2013 56.","DOI":"10.1053\/j.jvca.2005.03.026"},{"key":"2021072121212171600_i2590-017X-3-3-113-b44","doi-asserted-by":"crossref","unstructured":"Amar D, Goenka A, Zhang H, Park B, Thaler HT. Leukocytosis and increased risk of atrial fibrillation after general thoracic surgery. Ann Thorac Surg. 2006; 82: 1057\u2013 1061.","DOI":"10.1016\/j.athoracsur.2006.03.103"},{"key":"2021072121212171600_i2590-017X-3-3-113-b45","doi-asserted-by":"crossref","unstructured":"Lazzerini PE, Capecchi PL, Laghi-Pasini F. Long QT syndrome: an emerging role for inflammation and immunity. Front Cardiovasc Med. 2015; 2: 26.","DOI":"10.3389\/fcvm.2015.00026"},{"key":"2021072121212171600_i2590-017X-3-3-113-b46","doi-asserted-by":"crossref","unstructured":"Petkova-Kirova PS, Gursoy E, Mehdi H, McTiernan CF, London B, Salama G. Electrical remodeling of cardiac myocytes from mice with heart failure due to the overexpression of tumor necrosis factor-alpha. Am J Physiol Heart Circ Physiol. 2006; 290: H2098\u2013 H2107.","DOI":"10.1152\/ajpheart.00097.2005"},{"key":"2021072121212171600_i2590-017X-3-3-113-b47","doi-asserted-by":"crossref","unstructured":"Wang J, Wang H, Zhang Y, Gao H, Nattel S, Wang Z. Impairment of HERG K(+) channel function by tumor necrosis factor-alpha: role of reactive oxygen species as a mediator. J Biol Chem. 2004; 279: 13289\u2013 13292.","DOI":"10.1074\/jbc.C400025200"},{"key":"2021072121212171600_i2590-017X-3-3-113-b48","doi-asserted-by":"crossref","unstructured":"Lazzerini PE, Laghi-Pasini F, Bertolozzi I, et al. Systemic inflammation as a novel QT-prolonging risk factor in patients with torsades de pointes. Heart (British Cardiac Society). 2017; 103: 1821\u2013 1829.","DOI":"10.1136\/heartjnl-2016-311079"},{"key":"2021072121212171600_i2590-017X-3-3-113-b49","doi-asserted-by":"crossref","unstructured":"Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. 2015; 12: 230\u2013 243.","DOI":"10.1038\/nrcardio.2015.2"},{"key":"2021072121212171600_i2590-017X-3-3-113-b50","doi-asserted-by":"crossref","unstructured":"Lazzerini PE, Laghi-Pasini F, Acampa M, et al. Systemic inflammation rapidly induces reversible atrial electrical remodeling: the role of interleukin-6-mediated changes in connexin expression. J Am Heart Assoc. 2019; 8: e011006.","DOI":"10.1161\/JAHA.118.011006"},{"key":"2021072121212171600_i2590-017X-3-3-113-b51","doi-asserted-by":"crossref","unstructured":"Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J. 2004; 25: 1100\u2013 1107.","DOI":"10.1016\/j.ehj.2004.04.025"},{"key":"2021072121212171600_i2590-017X-3-3-113-b52","doi-asserted-by":"crossref","unstructured":"Pasquie JL, Sanders P, Hocini M, et al. Fever as a precipitant of idiopathic ventricular fibrillation in patients with normal hearts. J Cardiovasc Electrophysiol. 2004; 15: 1271\u2013 1276.","DOI":"10.1046\/j.1540-8167.2004.04388.x"},{"key":"2021072121212171600_i2590-017X-3-3-113-b53","doi-asserted-by":"crossref","unstructured":"Muller D, Agrawal R, Arntz HR. How sudden is sudden cardiac death? Circulation . 2006; 114: 1146\u2013 1150.","DOI":"10.1161\/CIRCULATIONAHA.106.616318"},{"key":"2021072121212171600_i2590-017X-3-3-113-b54","doi-asserted-by":"crossref","unstructured":"Fabre A, Sheppard MN. Sudden adult death syndrome and other non-ischaemic causes of sudden cardiac death. Heart (British Cardiac Society). 2006; 92: 316\u2013 320.","DOI":"10.1136\/hrt.2004.045518"},{"key":"2021072121212171600_i2590-017X-3-3-113-b55","doi-asserted-by":"crossref","unstructured":"Patruno N, Pontillo D, Achilli A, Ruggeri G, Critelli G. Electrocardiographic pattern of Brugada syndrome disclosed by a febrile illness: clinical and therapeutic implications. Europace. 2003; 5: 251\u2013 255.","DOI":"10.1016\/S1099-5129(03)00029-1"},{"key":"2021072121212171600_i2590-017X-3-3-113-b56","doi-asserted-by":"crossref","unstructured":"Le RQ, Li L, Yuan W, Shord SS, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018; 23: 943\u2013 947.","DOI":"10.1634\/theoncologist.2018-0028"},{"key":"2021072121212171600_i2590-017X-3-3-113-b57","doi-asserted-by":"crossref","unstructured":"Buckley LF, Abbate A. Interleukin-1 blockade in cardiovascular diseases: a clinical update. Eur Heart J. 2018; 39: 2063\u2013 2069.","DOI":"10.1093\/eurheartj\/ehy128"},{"key":"2021072121212171600_i2590-017X-3-3-113-b58","doi-asserted-by":"crossref","unstructured":"Asnani A. Cardiotoxicity of immunotherapy: incidence, diagnosis, and management. Curr Oncol Rep. 2018; 20: 44.","DOI":"10.1007\/s11912-018-0690-1"},{"key":"2021072121212171600_i2590-017X-3-3-113-b59","doi-asserted-by":"crossref","unstructured":"Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016; 3: 16011.","DOI":"10.1038\/mto.2016.11"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/3\/3\/113\/2871006\/i2590-017x-3-3-113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/3\/3\/113\/2871006\/i2590-017x-3-3-113.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:48:13Z","timestamp":1765475293000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/3\/3\/article-p113.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,20]]},"references-count":59,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,7,20]]},"published-print":{"date-parts":[[2020,8,3]]}},"URL":"https:\/\/doi.org\/10.36401\/jipo-20-10","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,20]]}}}